NGNE
vs
S&P 500
NGNE
S&P 500
Over the past 12 months, NGNE has underperformed S&P 500, delivering a return of -13% compared to the S&P 500's +14% growth.
Stocks Performance
NGNE vs S&P 500
Performance Gap
NGNE vs S&P 500
Performance By Year
NGNE vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Neurogene Inc
Glance View
Neurogene Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2014-03-07. Neurogene Inc., formerly Neoleukin Therapeutics, Inc., is focused on developing genetic medicines for patients and their families affected by rare, devastating neurological diseases. The firm is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. The firm's product candidate, NGN-401, is an investigational adeno-associated virus (AAV9) gene therapy candidate for Rett syndrome purposefully designed and administered to maximize therapeutic activity while averting transgene overexpression toxicities. The firm is also developing NGN-101 for the treatment of CLN5 Batten disease. The company is advancing multiple discovery-stage candidates leveraging its EXACT transgene regulation technology.
